Preclinical News and Research

RSS

Promising vaccine may provide new treatment option for patients with HER2-positive cancers

Treatment with a HER2-targeted therapeutic cancer vaccine provided clinical benefit to several patients with metastatic HER2-positive cancers who had not previously been treated with a HER2-targeted therapeutic, according to data from a phase I clinical trial presented at the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, held Sept. 30-Oct. 3.

30 Sep 2018

Synthetic DNA vaccine targets proteins overexpressed in several types of cancer

Scientists at The Wistar Institute have implemented a novel structurally designed synthetic DNA vaccine to simultaneously target multiple members of a family of proteins that are specifically overexpressed in several types of cancer.

28 Sep 2018

Bioaxone Biosciences receives Fast-Track SBIR grant to assess potential of Rho Kinase 2 inhibitor

BioAxone BioSciences, Inc. announced today the receipt of a Fast-Track grant from the National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health, as part of the agency's Small Business Innovation Research Program.

27 Sep 2018

Cidara initiates Phase 3 clinical trial to evaluate efficacy, safety of rezafungin to treat invasive candidiasis

Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the first trial site has been activated for ReSTORE, a Phase 3 clinical trial evaluating the efficacy and safety of the company's lead antifungal, rezafungin, to treat candidemia and invasive candidiasis.

27 Sep 2018

FLX Bio treats first patient in its Phase 1/2 clinical trial of FLX475 for treating various advanced cancers

FLX Bio, Inc., a clinical-stage, biopharmaceutical company focused on the development of oral small-molecule drugs that target drivers of cancer and other immune-related disorders, today announced that the first patient has been treated in its Phase 1/2 clinical trial of FLX475 in patients with various advanced cancers. FLX475 is an oral, small molecule CCR4 antagonist that selectively inhibits migration of regulatory T cells into the tumor microenvironment.

27 Sep 2018

Fina Biosolutions receives patent for expression and purification of the conjugate vaccine protein

Fina Biosolutions announces that the United States Patent and Trademark Office has issued a patent for expression and purification of the conjugate vaccine protein CRM197 in E. coli.

27 Sep 2018

Decibel obtains exclusive license to commercialize ORC-13661 for preventing hearing, balance disorders

Decibel Therapeutics and Oricula Therapeutics today announced that Decibel has obtained an exclusive, worldwide license to the development and commercialization of ORC-13661, an oral medication developed by Oricula Therapeutics for the prevention of hearing loss and balance disorders that can occur following treatment of severe infections with aminoglycoside antibiotics.

27 Sep 2018

Crown Bioscience announces successful validation of well-characterized prostate cancer PDX models

Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, has announced the addition of unique, well characterized, fully annotated patient-derived xenograft models of prostate cancer.

27 Sep 2018

OrthoSera presents first-in-man study results of hyperacute serum in knee osteoarthritis

OrthoSera GmbH, an orthobiologics company developing serum-based solutions for musculoskeletal indications announces results of its first-in-man pilot clinical study of hyperacute serum on 36 patients in knee osteoarthritis.

27 Sep 2018

CIRM approves $1.6M grant to help bring human islet-like organoids to diabetic patients

Approximately 1.25 million Americans are living with type 1 diabetes, with an additional 40,000 people newly diagnosed every year.

27 Sep 2018

New approach for bone marrow transplant could make it safer and more effective for patients

Two recent studies in the journal Leukemia present a new approach for bone marrow donation and transplant that preclinical laboratory tests suggest could make the life-saving procedure safer and more effective for patients.

26 Sep 2018

Mesoblast’s MPC therapy for children featured at symposium for congenital heart disease

Mesoblast Limited today announced that Mesoblast's proprietary allogeneic mesenchymal precursor cell heart failure product candidate MPC-150-IM for use in children with hypoplastic left heart syndrome was featured at the First Cardiac Regenerative Symposium for Congenital Heart Disease in Baltimore, Maryland on the weekend.

26 Sep 2018

FDA grants Orphan Drug Designation to Myelo001 for treatment of Acute Radiation Syndrome

Myelo Therapeutics GmbH announced today that the US Food and Drug Administration has granted an Orphan Drug Designation to its orally applied new chemical entity Myelo001 for the treatment of Acute Radiation Syndrome.

25 Sep 2018

Cerevance starts dosing in Phase I clinical trial of CVN424 for treatment of Parkinson's disease

Cerevance, a clinical-stage drug discovery and development company focused on brain diseases, today announced the start of dosing in a Phase I first-in-human clinical trial of CVN424, an oral compound being developed for symptomatic treatment of Parkinson's disease.

25 Sep 2018

Toxicological evaluation and dosimetry estimation of potential PET radiotracer

The SR101 N-(3-[18F]Fluoropropyl) sulfonamide ([18F]SRF101) is a Sulforhodamine 101 derivative that was previously synthesized by our group.

25 Sep 2018

Lumos acquires license for LUM-201 drug that promotes secretion of growth hormone

Lumos Pharma, Inc., a clinical stage biopharmaceutical company focused on development and commercialization of therapeutics for rare and neglected diseases, today announced that it has acquired the license for LUM-201, an investigational orally administered small molecule that promotes secretion of growth hormone from the pituitary gland, from Ammonett Pharma LLC.

24 Sep 2018

FDA lifts partial clinical hold that paused enrollment of new patients in tazemetosta clinical trials

Epizyme, Inc., a clinical-stage company developing novel epigenetic therapies, today announced the U.S. Food and Drug Administration has lifted the partial clinical hold that had paused U.S.-based enrollment of new patients in its tazemetostat clinical trials.

24 Sep 2018

Preclinical News and Research

Promising vaccine may provide new treatment option for patients with HER2-positive cancers

Synthetic DNA vaccine targets proteins overexpressed in several types of cancer

Bioaxone Biosciences receives Fast-Track SBIR grant to assess potential of Rho Kinase 2 inhibitor

Cidara initiates Phase 3 clinical trial to evaluate efficacy, safety of rezafungin to treat invasive candidiasis

FLX Bio treats first patient in its Phase 1/2 clinical trial of FLX475 for treating various advanced cancers

Fina Biosolutions receives patent for expression and purification of the conjugate vaccine protein

Decibel obtains exclusive license to commercialize ORC-13661 for preventing hearing, balance disorders

Crown Bioscience announces successful validation of well-characterized prostate cancer PDX models

OrthoSera presents first-in-man study results of hyperacute serum in knee osteoarthritis

CIRM approves $1.6M grant to help bring human islet-like organoids to diabetic patients

New approach for bone marrow transplant could make it safer and more effective for patients

Mesoblast’s MPC therapy for children featured at symposium for congenital heart disease

FDA grants Orphan Drug Designation to Myelo001 for treatment of Acute Radiation Syndrome

Cerevance starts dosing in Phase I clinical trial of CVN424 for treatment of Parkinson's disease

Toxicological evaluation and dosimetry estimation of potential PET radiotracer

Lumos acquires license for LUM-201 drug that promotes secretion of growth hormone

FDA lifts partial clinical hold that paused enrollment of new patients in tazemetosta clinical trials

Columbia University announces winners of 2018 Louisa Gross Horwitz Prize

New research suggests power of zebrafish as tool for cancer drug discovery

First-in-human phase 0 study shows clinically-relevant activity of new drug in glioblastoma

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics